Latest research on Dasatinib

Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.

Dasatinib side effects

However, Dasatinib increased the number of M2 macrophages in lung parenchyma (712.3%) and granuloma (336.5%) in animals with acute silicosis (Fig 6, Table F in S1 File). [source, 2016]
In the model of acute silicosis used herein, Dasatinib improved lung mechanics and led to a reduction of fraction area of granuloma, neutrophils in lung tissue and granuloma, M1 macrophages in lung parenchyma and granuloma, fraction area of collapsed alveoli, collagen fiber content in lung parenchyma, protein levels of IL-1β, TNF-α, and TGF-β, and increased M2 macrophages in lung parenchyma and granuloma. [source, 2016]
In vitro studies showed that Dasatinib led to reduced expression of iNOS and increased expression of arginase and MMP-9. [source, 2016]
In our experiments, Dasatinib increased the amount of M2 macrophages and reduced collagen deposition in lung parenchyma and granuloma. [source, 2016]
Dasatinib, a second-generation TYROSINE kinase inhibitor, was chosen for our study because it is safe, presents potent antifibrotic effects, and has a lower cost [8]. [source, 2016]
Treatment of macrophages with Dasatinib increases production of IL-10 while suppressing production of TNF-α [42]. [source, 2016]
Our recent work has shown that the BCR-ABL/Src kinase inhibitor Dasatinib decreases CK2 activity and PRH phosphorylation resulting in increased PRH-dependent repression of Vegf and Vegfr-1 in leukaemic cells [91]. [source, 2016]
Since Src activity is increased in many cancer types resulting in increased CK2 activity, Dasatinib could restore PRH function in several disease states. [source, 2016]
The combined treatment with Dasatinib (5 μM) and Doxorubicin (25 nM) significantly decreased cell viability of hMSC-TERT20-CE8 compared to treatment with Doxorubicin alone: 0.50 (95% CI: 0.48; 0.52) versus 0.78 (95% CI: 0.69; 0.90), respectively, p = 0.002. [source, 2016]
Our results demonstrated that combining Dasatinib and Doxorubicin decreases cell viability of a cell line less sensitive to Doxorubicin treatment and that targeting EGFR may not be a future treatment strategy for sarcoma patient. [source, 2016]